The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
What are the expectations and preferences of patients with ovarian cancer to a maintenance therapy? A NOGGO/GCIG/ENGOT-ov22 survey (Expression IV) in 2101 patients.
 
Irena Rohr
No Relationships to Disclose
 
Maren Keller
No Relationships to Disclose
 
Radoslav Chekerov
No Relationships to Disclose
 
Gülten Oskay-Özcelik
Consulting or Advisory Role - Amgen; Novartis; PharmaMar; Roche
 
Rolf Richter
No Relationships to Disclose
 
Michaela Heinrich
No Relationships to Disclose
 
Cagatay Taskiran
No Relationships to Disclose
 
Florence Joly
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Ferring; Janssen; Novartis; Pfizer (Inst); Roche; Tesaro (Inst)
Research Funding - Astellas Pharma (Inst); Janssen (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Janssen; Pfizer; Roche
 
Pia Wolfrum-Ristau
No Relationships to Disclose
 
Andreja Gornjec
No Relationships to Disclose
 
Ignace Vergote
Consulting or Advisory Role - Amgen (Inst); Array Biopharma (Inst); AstraZeneca (Inst); Biogen (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Endocyte (Inst); Fresenius (Inst); GE Healthcare (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Hampton Medical Conferences (Inst); Intuitive Surgical (Inst); Janssen-Cilag (Inst); Kendle (Inst); Lilly (Inst); MedImmune (Inst); Menarini (Inst); Merck Sharp & Dohme (Inst); Morphotek (Inst); Nektar (Inst); Novo Nordisk (Inst); Oasmia Pharmaceutical AB (Inst); PharmaMar (Inst); Phillips Gilmore Oncology (Inst); Quintiles (Inst); Roche (Inst); Sanofi (Inst); Schering-Plough (Inst); Sigma-Tau (Inst); Telik (Inst); TRM Oncology (Inst)
Research Funding - Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Eisai (Inst); Exelixis (Inst); Fresenius Biotech (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Janssen-Cilag (Inst); Merck Sharp & Dohme (Inst); Merrimack (Inst); Morphotek (Inst); Nektar (Inst); Nerviano Medical Sciences (Inst); Novartis (Inst); Pfizer (Inst); Proacta (Inst); Quintiles (Inst); Roche (Inst); Sandoz (Inst); Sanofi (Inst); Schering-Plough (Inst); Vifor Pharma (Inst); Wyeth (Inst)
Travel, Accommodations, Expenses - AstraZeneca; GCI Health; Oasmia Pharmaceutical AB; PharmaMar; Roche
 
Patrick Achimas
No Relationships to Disclose
 
Domenica Lorusso
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; PharmaMar; Roche
Research Funding - PharmaMar (Inst)
Travel, Accommodations, Expenses - PharmaMar; Roche
 
Johanna Unelma Maenpaa
Honoraria - AstraZeneca; Roche; SOBI
Consulting or Advisory Role - AstraZeneca; Roche
 
Jalid Sehouli
Honoraria - AstraZeneca; PharmaMar; Roche; Tesaro
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Novocure; Roche; Tesaro
Research Funding - Amgen (Inst); Bayer (Inst); Lilly (Inst); Novartis (Inst)